1-isopropyl-4-(trifluoromethyl)-1H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-isopropyl-4-(trifluoromethyl)-1H-imidazole
• 英文别名: 1-Propan-2-yl-4-(trifluoromethyl)imidazole；1-propan-2-yl-4-(trifluoromethyl)imidazole
• 化学式: C₇H₉F₃N₂
• 分子量: 178.157
• InChiKey: FUZVGMGAWYLKAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-isopropyl-4-(trifluoromethyl)-1H-imidazole 在 正丁基锂 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 为溶剂， 以62.4 %的产率得到2-bromo-1-isopropyl-4-(trifluoromethyl)-1H-imidazole
  参考文献：
  名称：

  [EN] SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
  [FR] MODULATEURS CYCLIQUES DE TYPE SPIROCYCLIQUES DE LA BIOSYNTHÈSE DU CHOLESTÉROL ET LEUR UTILISATION POUR FAVORISER LA REMYÉLINISATION

  摘要：

  The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

  公开号：

  WO2023097233A1
• 作为产物：
  描述：

  2-碘代丙烷 、 4-(三氟甲基)-1H-咪唑 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以76.4 %的产率得到1-isopropyl-4-(trifluoromethyl)-1H-imidazole
  参考文献：
  名称：

  [EN] SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
  [FR] MODULATEURS CYCLIQUES DE TYPE SPIROCYCLIQUES DE LA BIOSYNTHÈSE DU CHOLESTÉROL ET LEUR UTILISATION POUR FAVORISER LA REMYÉLINISATION

  摘要：

  The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

  公开号：

  WO2023097233A1

文献信息

• PTERIDINONE COMPOUNDS AND USES THEREOF
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190322673A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I的化合物或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175560A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R 2 , R 3 , R 4 , p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类钠通道抑制剂化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由式I给出：其中X、Y、Z、R2、R3、R4、p和q如本文所述，以及制备和使用该化合物的方法以及含有该化合物的药物组合物。
• PARTHENOLIDE DERIVATIVES AND THEIR MODULATION OF PROCESSES CONTROLLED BY REGULATED TRANSLATION
  申请人：PENTHALA Narsimha Reddy

  公开号：US20160083397A1

  公开（公告）日：2016-03-24

  The present invention provides parthenolide derivatives. In particular, the present invention provides parthenolide derivatives that modulate processes controlled by regulated mRNA translation and have anticancer activity.

  本发明提供了蒿甙衍生物。特别地，本发明提供了能够调节由调节mRNA翻译控制的过程并具有抗癌活性的蒿甙衍生物。
• Diazole amides
  申请人：CHEMOCENTRYX, INC.

  公开号：US10342781B2

  公开（公告）日：2019-07-09

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

  所提供的化合物可作为 CCR1 受体的强效拮抗剂，并具有体内抗炎活性。这些化合物是重氮内酰胺衍生物，可用于药物组合物、治疗 CCR1 介导的疾病的方法，并可在鉴定竞争性 CCR1 拮抗剂的试验中用作对照。
• Pteridinone compounds and uses thereof
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US11059826B2

  公开（公告）日：2021-07-13

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式 I 的化合物或其药学上可接受的盐、其药物组合物及其用于治疗细胞增殖性疾病（如癌症）的方法。